Eli Lilly CDR (CAD Hedged)
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 43K
- Market Cap
- $859.4B
- Introduction
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
A Study of LY2216684 and Digoxin in Healthy Subjects
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 30
- Registration Number
- NCT01266590
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, United States
A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2018-10-23
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 24
- Registration Number
- NCT01263223
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Austin, Texas, United States
A Study of LY2216684 and Theophylline in Healthy Subjects
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2019-07-08
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT01263106
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study of LY2216684 in Healthy Participants Receiving Albuterol or Propanolol
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: placebo for LY2216684
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT01263197
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Evansville, Indiana, United States
A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 47
- Registration Number
- NCT01263093
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Study of LY2216684 and Warfarin in Healthy Subjects
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01263119
- Locations
- πΊπΈ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States
A Phase 1b Trial in Patients With Renal Cell Cancer
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2019-01-10
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 21
- Registration Number
- NCT01258348
- Locations
- π¨π¦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Montreal, Quebec, Canada
A Study to Evaluate the Pharmacokinetics of LY2624803 in Subjects With Hepatic Impairment
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2011-06-03
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT01257178
- Locations
- π·πΊ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow, Russian Federation
A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer
- Conditions
- Breast CancerMetastatic Breast Cancer
- Interventions
- Biological: Ramucirumab
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 7
- Registration Number
- NCT01256567
- Locations
- π―π΅
ImClone Investigational Site, Osaka, Japan
π―π΅Imclone Investigational Site, Nagoya, Japan
Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
- Conditions
- Adenocarcinoma
- Interventions
- Biological: Ramucirumab (IMC-1121B )
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2014-06-18
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 6
- Registration Number
- NCT01253525
- Locations
- π―π΅
ImClone Investigational Site, Osaka, Japan